Molecular dynamic simulation reveals spider antimicrobial peptide Latarcin-1 and human eosinophil cationic protein as peptide inhibitors of SARS-CoV-2 variants

References

• Abraham, M. J., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1–2, 19–25. https://doi.org/10.1016/j.softx.2015.06.001
   Google Scholar
• Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A, National Study Group for COVID-19 Vaccination. (2021). Effectiveness of the BNT162b2 COVID-19 vaccine against the B. 1.1. 7 and B. 1.351 variants. The New England Journal of Medicine, 385(2), 187–189. https://doi.org/10.1056/NEJMc2104974
   PubMed Web of Science ®Google Scholar
• Aldeghi, M., Bodkin, M. J., Knapp, S., & Biggin, P. C. (2017). Statistical analysis on the performance of Molecular Mechanics Poisson–Boltzmann Surface Area versus absolute binding free energy calculations: Bromodomains as a case study. Journal of Chemical Information and Modeling, 57(9), 2203–2221. https://doi.org/10.1021/acs.jcim.7b00347
   PubMed Web of Science ®Google Scholar
• Azad, T., Singaravelu, R., Crupi, M. J. F., Jamieson, T., Dave, J., Brown, E. E. F., Rezaei, R., Taha, Z., Boulton, S., Martin, N. T., Surendran, A., Poutou, J., Ghahremani, M., Nouri, K., Whelan, J. T., Duong, J., Tucker, S., Diallo, J.-S., Bell, J. C., & Ilkow, C. S. (2020). Implications for SARS-CoV-2 vaccine design: Fusion of spike glycoprotein transmembrane domain to receptor-binding domain induces trimerization. Membranes, 10(9), 215. https://doi.org/10.3390/membranes10090215
   PubMed Web of Science ®Google Scholar
• Bakhshandeh, B., Sorboni, S. G., Javanmard, A.-R., Mottaghi, S. S., Mehrabi, M.-R., Sorouri, F., Abbasi, A., & Jahanafrooz, Z. (2021). Variants in ACE2; potential influences on virus infection and COVID-19 severity. Infection, Genetics and Evolution, 90, 104773. https://doi.org/10.1016/j.meegid.2021.104773
   PubMed Web of Science ®Google Scholar
• Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., & Dabrera, G. (2021). Effectiveness of COVID-19 vaccines against the B. 1.617. 2 (Delta) variant. New England Journal of Medicine.385(7),585-594.https://doi.org/10.1056/NEJMoa2108891
   Google Scholar
• Burley, S. K., Berman, H. M., Kleywegt, G. J., Markley, J. L., Nakamura, H., & Velankar, S. (2017). Protein Data Bank (PDB): The single global macromolecular structure archive. Methods in Molecular Biology (Clifton, N.J.), 1607, 627–641. https://doi.org/10.1007/978-1-4939-7000-1_26
   PubMedGoogle Scholar
• Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., & Lu, M. (2020). Favipiravir versus arbidol for COVID-19: A randomized clinical trial. MedRxiv.12:683296. https://doi.org/10.1101/2020.03.17.20037432
   Google Scholar
• Chen, J., Lau, Y. F., Lamirande, E. W., Paddock, C. D., Bartlett, J. H., Zaki, S. R., & Subbarao, K. (2010). Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. Journal of Virology, 84(3), 1289–1301. https://doi.org/10.1128/JVI.01281-09
   PubMed Web of Science ®Google Scholar
• Christensen, P. A., Olsen, R. J., Long, S. W., Snehal, R., Davis, J. J., Ojeda Saavedra, M., Reppond, K., Shyer, M. N., Cambric, J., Gadd, R., Thakur, R. M., Batajoo, A., Mangham, R., Pena, S., Trinh, T., Kinskey, J. C., Williams, G., Olson, R., Gollihar, J., & Musser, J. M. (2022). Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston, Texas. The American Journal of Pathology, 192(4), 642–652. https://doi.org/10.1016/j.ajpath.2021.10.019
   PubMed Web of Science ®Google Scholar
• Darby, A. C., & Hiscox, J. A. (2021). COVID-19: Variants and vaccination. British Medical Journal Publishing Group, 372,n771. https://doi.org/10.1136/bmj.n771
   Google Scholar
• Dubovskii, P. V., Volynsky, P. E., Polyansky, A. A., Karpunin, D. V., Chupin, V. V., Efremov, R. G., & Arseniev, A. S. (2008). Three-dimensional structure/hydrophobicity of latarcins specifies their mode of membrane activity. Biochemistry, 47(11), 3525–3533. https://doi.org/10.1021/bi702203w
   PubMed Web of Science ®Google Scholar
• Fadel, R., Morrison, A. R., Vahia, A., Smith, Z. R., Chaudhry, Z., Bhargava, P., Miller, J., Kenney, R. M., Alangaden, G., Ramesh, M. S., & Henry Ford COVID-19 Management Task Force. (2020). Early short-course corticosteroids in hospitalized patients with COVID-19. Clinical Infectious Diseases, 71(16), 2114–2120. https://doi.org/10.1093/cid/ciaa601
   PubMed Web of Science ®Google Scholar
• Gao, J., Tian, Z., & Yang, X. (2020). Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience Trends, 14(1), 72–73.
   PubMed Web of Science ®Google Scholar
• Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10(5), 449–461. https://doi.org/10.1517/17460441.2015.1032936
   PubMed Web of Science ®Google Scholar
• Greer, S. L., King, E. J., da Fonseca, E. M., & Peralta-Santos, A. (2020). The comparative politics of COVID-19: The need to understand government responses. Global Public Health, 15(9), 1413–1416. https://doi.org/10.1080/17441692.2020.1783340
   PubMed Web of Science ®Google Scholar
• Henderson, R., Edwards, R. J., Mansouri, K., Janowska, K., Stalls, V., Gobeil, S. M. C., Kopp, M., Li, D., Parks, R., Hsu, A. L., Borgnia, M. J., Haynes, B. F., & Acharya, P. (2020). Controlling the SARS-CoV-2 spike glycoprotein conformation. Nature Structural & Molecular Biology, 27(10), 925–933. https://doi.org/10.1038/s41594-020-0479-4
   PubMed Web of Science ®Google Scholar
• Huang, Y., Yang, C., Xu, X.-F., Xu, W., & Liu, S.-W. (2020). Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19. Acta Pharmacologica Sinica, 41(9), 1141–1149. https://doi.org/10.1038/s41401-020-0485-4
   PubMed Web of Science ®Google Scholar
• Kanjanaumporn, J., Aeumjaturapat, S., Snidvongs, K., Seresirikachorn, K., & Chusakul, S. (2020). Smell and taste dysfunction in patients with SARS-CoV-2 infection: A review of epidemiology, pathogenesis, prognosis, and treatment options. Asian Pacific Journal of Allergy and Immunology, 38(2), 69–77. https://doi.org/10.12932/AP-030520-0826
   PubMed Web of Science ®Google Scholar
• Ke, Z., Oton, J., Qu, K., Cortese, M., Zila, V., McKeane, L., Nakane, T., Zivanov, J., Neufeldt, C. J., Cerikan, B., Lu, J. M., Peukes, J., Xiong, X., Kräusslich, H.-G., Scheres, S. H. W., Bartenschlager, R., & Briggs, J. A. G. (2020). Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature, 588(7838), 498–502. https://doi.org/10.1038/s41586-020-2665-2
   PubMed Web of Science ®Google Scholar
• Kenny, G., & Mallon, P. W. (2021). COVID19-clinical presentation and therapeutic considerations. Biochemical and Biophysical Research Communications, 538, 125–131. https://doi.org/10.1016/j.bbrc.2020.11.021
   PubMed Web of Science ®Google Scholar
• Kolilekas, L., Loverdos, K., Giannakaki, S., Vlassi, L., Levounets, A., Zervas, E., & Gaga, M. (2020). Can steroids reverse the severe COVID‐19 induced “cytokine storm”? Journal of Medical Virology, 92(11), 2866–2869. https://doi.org/10.1002/jmv.26165
   PubMed Web of Science ®Google Scholar
• Kumari, R., Kumar, R., Consortium, O. S. D. D., Lynn, A., & Open Source Drug Discovery Consortium. (2014). g_mmpbsa—A GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54(7), 1951–1962. https://doi.org/10.1021/ci500020m
   PubMed Web of Science ®Google Scholar
• Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., & Wang, X. (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature, 581(7807), 215–220. https://doi.org/10.1038/s41586-020-2180-5
   PubMed Web of Science ®Google Scholar
• Li, D., Chen, P., Shi, T., Mehmood, A., & Qiu, J. (2021). HD5 and LL-37 inhibit SARS-CoV and SARS-CoV-2 binding to human ACE2 by molecular simulation. Interdisciplinary Sciences, Computational Life Sciences, 13(4), 766–777. https://doi.org/10.1007/s12539-021-00462-3
   PubMed Web of Science ®Google Scholar
• Li, D., Wang, C., Wang, S., Mehmood, A., Gu, J., Cheng, X., Chen, P., Qiu, J., Zhao, J., Wang, J., & Wei, D. (2022). Discovery of a natural product with potent efficacy against SARS-CoV-2 by drug screening. Interdisciplinary Sciences, Computational Life Sciences, 14(1), 55–63. https://doi.org/10.1007/s12539-021-00477-w
   PubMed Web of Science ®Google Scholar
• Li, J., Wang, Y., Liu, Y., Zhang, Z., Zhai, Y., Dai, Y., Wu, Z., Nie, X., & Du, L. (2022). Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: A systematic review. European Journal of Medical Research, 27(1), 26. https://doi.org/10.1186/s40001-022-00647-6
   PubMed Web of Science ®Google Scholar
• Miller, B. R., III, McGee, T. D., Jr., Swails, J. M., Homeyer, N., Gohlke, H., & Roitberg, A. E. (2012). MMPBSA. py: An efficient program for end-state free energy calculations. Journal of Chemical Theory and Computation, 8(9), 3314–3321. https://doi.org/10.1021/ct300418h
   PubMed Web of Science ®Google Scholar
• Moore, S. C., Penrice-Randal, R., Alruwaili, M., Randle, N., Armstrong, S., Hartley, C., Haldenby, S., Dong, X., Alrezaihi, A., Almsaud, M., Bentley, E., Clark, J., García-Dorival, I., Gilmore, P., Han, X., Jones, B., Luu, L., Sharma, P., Shawli, G., … Hiscox, J. A. (2020). Amplicon-based detection and sequencing of SARS-CoV-2 in nasopharyngeal swabs from patients with COVID-19 and identification of deletions in the viral genome that encode proteins involved in interferon antagonism. Viruses, 12(10), 1164. https://doi.org/10.3390/v12101164
   PubMed Web of Science ®Google Scholar
• Morse, J. S., Lalonde, T., Xu, S., & Liu, W. R. (2020). Learning from the past: Possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem, 21(5), 730–738. https://doi.org/10.1002/cbic.202000047
   PubMed Web of Science ®Google Scholar
• Nguyen, H. L., Lan, P. D., Thai, N. Q., Nissley, D. A., O'Brien, E. P., & Li, M. S. (2020). Does SARS-CoV-2 bind to human ACE2 more strongly than does SARS-CoV? The Journal of Physical Chemistry B, 124(34), 7336–7347. https://doi.org/10.1021/acs.jpcb.0c04511
   PubMed Web of Science ®Google Scholar
• Qin, L., Hartley, A., Turner, P., Elmes, R. B., & Jolliffe, K. A. (2016). Macrocyclic squalamine: Anion receptors with high sulfate binding affinity and selectivity in aqueous media. Chemical Science, 7(7), 4563–4572. https://doi.org/10.1039/c6sc01011c
   PubMed Web of Science ®Google Scholar
• Rabi, F. A., Al Zoubi, M. S., Kasasbeh, G. A., Salameh, D. M., & Al-Nasser, A. D. (2020). SARS-CoV-2 and coronavirus disease 2019: What we know so far. Pathogens (Basel, Switzerland), 9(3), 231. https://doi.org/10.3390/pathogens9030231
   PubMed Web of Science ®Google Scholar
• Rosa, S. G. V., & Santos, W. C. (2020). Clinical trials on drug repositioning for COVID-19 treatment. Revista Panamericana de Salud Publica = Pan American Journal of Public Health, 44, e40. https://doi.org/10.26633/RPSP.2020.40
   PubMed Web of Science ®Google Scholar
• Seeliger, D., & de Groot, B. L. (2010). Ligand docking and binding site analysis with PyMOL and Autodock/Vina. Journal of Computer-Aided Molecular Design, 24(5), 417–422. https://doi.org/10.1007/s10822-010-9352-6
   PubMed Web of Science ®Google Scholar
• Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020). Structural basis of receptor recognition by SARS-CoV-2. Nature, 581(7807), 221–224. https://doi.org/10.1038/s41586-020-2179-y
   PubMed Web of Science ®Google Scholar
• Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., Fouche, L., Louw, C., Tameris, M., Singh, N., Goga, A., Dheda, K., Grobbelaar, C., Kruger, G., Carrim-Ganey, N., … 2019nCoV-501 Study Group. (2021). Efficacy of NVX-CoV2373 COVID-19 vaccine against the B. 1.351 variant. The New England Journal of Medicine, 384(20), 1899–1909. https://doi.org/10.1056/NEJMoa2103055
   PubMed Web of Science ®Google Scholar
• Simmonds, P., Tuplin, A., & Evans, D. J. (2004). Detection of genome-scale ordered RNA structure (GORS) in genomes of positive-stranded RNA viruses: Implications for virus evolution and host persistence. RNA (New York, N.Y.), 10(9), 1337–1351. https://doi.org/10.1261/rna.7640104
   PubMed Web of Science ®Google Scholar
• Sivapalasingam, S., Lederer, D. J., Bhore, R., Hajizadeh, N., Criner, G., Hosain, R., Mahmood, A., Giannelou, A., Somersan-Karakaya, S., & O’Brien, M. P. (2022). Efficacy and safety of sarilumab in hospitalized patients with COVID-19: A randomized clinical trial. Clinical Infectious Diseases.
   PubMed Web of Science ®Google Scholar
• Soga, S., Shirai, H., Kobori, M., & Hirayama, N. (2007). Use of amino acid composition to predict ligand-binding sites. Journal of Chemical Information and Modeling, 47(2), 400–406. https://doi.org/10.1021/ci6002202
   PubMed Web of Science ®Google Scholar
• Valdés-Tresanco, M. S., Valdés-Tresanco, M. E., Valiente, P. A., & Moreno, E. (2021). gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS. Journal of Chemical Theory and Computation, 17(10), 6281–6291. https://doi.org/10.1021/acs.jctc.1c00645
   PubMed Web of Science ®Google Scholar
• Wang, C., Greene, D. A., Xiao, L., Qi, R., & Luo, R. (2017). Recent developments and applications of the MMPBSA method. Frontiers in Molecular Biosciences, 4, 87. https://doi.org/10.3389/fmolb.2017.00087
   PubMed Web of Science ®Google Scholar
• Wang, F., Huang, S., Gao, R., Zhou, Y., Lai, C., Li, Z., Xian, W., Qian, X., Li, Z., Huang, Y., Tang, Q., Liu, P., Chen, R., Liu, R., Li, X., Tong, X., Zhou, X., Bai, Y., Duan, G., … Liu, L. (2020). Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. Cell Discovery, 6(1), 83. https://doi.org/10.1038/s41421-020-00231-4
   PubMed Web of Science ®Google Scholar
• Wang, F., Kream, R. M., & Stefano, G. B. (2020). Long-term respiratory and neurological sequelae of COVID-19. Medical Science Monitor, 26, e928996-1. https://doi.org/10.12659/MSM.928996
   Web of Science ®Google Scholar
• Xiong, Q., Xu, M., Li, J., Liu, Y., Zhang, J., Xu, Y., & Dong, W. (2021). Clinical sequelae of COVID-19 survivors in Wuhan, China: A single-centre longitudinal study. Clinical Microbiology and Infection, 27(1), 89–95. https://doi.org/10.1016/j.cmi.2020.09.023
   PubMed Web of Science ®Google Scholar
• Xu, X.-W., Wu, X.-X., Jiang, X.-G., Xu, K.-J., Ying, L.-J., Ma, C.-L., Li, S.-B., Wang, H.-Y., Zhang, S., Gao, H.-N., Sheng, J.-F., Cai, H.-L., Qiu, Y.-Q., & Li, L.-J. (2020). Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series. BMJ (Clinical Research ed.), 368, m606. https://doi.org/10.1136/bmj.m606
   PubMed Web of Science ®Google Scholar
• Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020). Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science (New York, N.Y.), 367(6485), 1444–1448. https://doi.org/10.1126/science.abb2762
   PubMed Web of Science ®Google Scholar
• Yao, L., Li, M., Wan, J. Y., Howard, S. C., Bailey, J. E., & Graff, J. C. (2022). Democracy and case fatality rate of COVID-19 at early stage of pandemic: A multicountry study. Environmental Science and Pollution Research International, 29(6), 8694–8704. https://doi.org/10.1007/s11356-021-16250-x
   PubMed Web of Science ®Google Scholar
• Yi, C., Sun, X., Ye, J., Ding, L., Liu, M., Yang, Z., Lu, X., Zhang, Y., Ma, L., Gu, W., Qu, A., Xu, J., Shi, Z., Ling, Z., & Sun, B. (2020). Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cellular & Molecular Immunology, 17(6), 621–630. https://doi.org/10.1038/s41423-020-0458-z
   PubMed Web of Science ®Google Scholar
• Zhao, Y., Kuang, M., Li, J., Zhu, L., Jia, Z., Guo, X., Hu, Y., Kong, J., Yin, H., Wang, X., & You, F. (2021). SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Research, 31(7), 818–820. https://doi.org/10.1038/s41422-021-00495-9
   PubMed Web of Science ®Google Scholar